华蟾素配合软坚化瘀加减方治疗非小细胞肺癌56例临床研究

Huachansu Combined with Ruanjianhuayu Plus-minus Prescriptions in the Teatment of Non-small Cell Lung Cancer

目的:观察华蟾素联合软坚化瘀加减方治疗非小细胞肺癌(NSCLC)的临床疗效。方法:选择NSCLC患者共56例,分为华蟾素联合软坚化瘀加减方组28例(以下称治疗组)及单药华蟾素组28例(以下称对照组),两组治疗期间均未行放、化疗。结果:治疗组和对照组有效率分别为21.4%和17.9%,无显著性差异(P>0.05);治疗组比对照组生活质量明显提高(P<0.05);临床症状改善率分别为92.9%和64.3%,有显著性差异(P<0.05);两组治疗后肿瘤相关抗原表达下降无显著性差异(P>0.05)。结论:华蟾素配合软坚化瘀加减方治疗非小细胞肺癌,可以改善临床症状,提高生活质量。

Objective：To observe Huachansu combined with Ruanjianhuayu plus-minus prescriptions in the treatment of non-small cell lung cancer.Methods：Fifty-six cases of non-small cell lung cancer were divided into the joint Huachansu to Ruanjianhuayu plus-minus prescriptions group of 28 patients（treatment group）and 28 cases of simple Huachansu group（control group）,two groups during treatment did not line radiotherapy and chemotherapy.Results：The rate of response was 21.4% in Huachansu combined with Ruanjianhuayu plus-minus prescriptions group,and 17.9% in control group respectively（P0.05）.The quality of life had a significant difference between treatment group and control group（P0.05）.The clinical symptoms improvement in treatment group and control group were 92.9% and 64.3%（P0.05）.Both of the two groups,the expression of tumors antigen reduced after treatment（P0.05）.Conclusion： Huachansu combined with Ruanjianhuayu plus-minus prescriptions in the treatment of non-small cell lung cancer（NSCLC） is able to improve the clinical symptoms and enhance the quality of life.